BioWorld

March 1, 2004

View Archived Issues

Genzyme Expands Oncology Portfolio, Buys ILEX For $1B

Continuing with a growth-by-acquisition theme, Genzyme Corp. late Thursday unveiled plans for a $1 billion stock purchase of cancer drug developer ILEX Oncology Inc. (BioWorld Today) Read More

Neurocrine Paying $95M For Wyeth's Portion Of Indiplon

Read More

Vasogen, Aphton Complete Offerings For Phase III Trials

Read More

GangaGen Developing Pipeline From Bacteriophage Research

Read More

Other News To Note

Read More